Trial Profile
A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Poly ICLC (Primary)
- Indications Astrocytoma; Glioma; Neurofibromatoses; Neurofibromatosis 1; Oligodendroglioma
- Focus Therapeutic Use
- 16 Jun 2021 Status changed from active, no longer recruiting to completed.
- 19 Sep 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2017 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.